🔗 Share this article

Given that America proceeds with unprecedented revisions to its vaccine schedules, one figure has surfaced in a surprising turn: Høeg, a Danish American sports physician and epidemiologist who first made her name by expressing skepticism about coronavirus vaccines during the pandemic and has focused upon potential deaths after COVID-19 immunization in her recent position at the US Food and Drug Administration (FDA).

Scheduled Changes to Pediatric Vaccine Schedule

Health officials had intended to announce sweeping revisions to the pediatric vaccine schedule earlier this month, synchronizing the US with Denmark’s immunization schedule, according to reports – a substantial departure that would put the US out of alignment with many the global community with little proof for public health gain. This reveal has been delayed until the next year.

In place of Vinay Prasad, Høeg is set to present at the meeting. She was just designated interim head of the FDA’s drug evaluation center, the fifth person to head the center this calendar year.

A Shift at the Regulatory Body

This interim role may indicate a tighter collaboration between the pharmaceutical and biologics divisions as Dr. Høeg and Dr. Prasad consolidate power at the regulatory agency – and it suggests a increased emphasis upon rolling back previously authorized immunizations at the FDA.

Dr. Høeg has often pushed for ending certain childhood vaccine recommendations in the US to become more like Denmark, a country with comprehensive healthcare and a population approximately the population of Wisconsin’s.

So far comments, she has continued to focus on vaccines – usually the purview of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of drug regulation.

Questions Over Background

Dr. Høeg has no obvious track record in medication creation, approval processes or management, which has been standard for past heads of the CBER. She has served at the FDA as a senior adviser to the FDA chief and CBER since spring.

“She appears not to have the requisite experience” for running the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She’s never run a clinical trial. She has no expertise in leading a large organization. She has no expertise in pharmaceutical oversight.”

Past heads of CBER would “grasp regulatory frameworks and the research of pharmaceutical innovation”, commented a former acting FDA commissioner. “Frankly, she lacks the kind of background that prior appointees who ran the center have had.”

CDER has an vast workload at the FDA, the former commissioner stated.

“The public just focuses on the novel medication approvals, but the generic program approves thousands of generic medications. There is also a biosimilars program, OTC medication office and so forth, and every single one must be supervised,” she noted. “The thing you overlook, that is the part that I always told people is going to come back to haunt you.”

Additionally, a major leadership element to the job, which oversees more than 5,000 employees. “It’s a huge management job, if you do it right,” she concluded.

Response and Contentious Initiatives

In response to concerns about Høeg’s credentials and whether this assignment represents increased cooperation among agency officials on vaccines, a spokesperson responded that the “inquiries stem from incorrect assumptions”.

“Her experience aligns with the functions of her job,” the spokesperson explained, pointing to the time Høeg spent guiding the agency head on “medication safety and approval science, including computerized risk analysis and shot safety tracking”.

As acting director, Høeg assumes responsibility for the agency head's new fast-track approval initiative, a controversial rapid medication authorization process that reportedly troubled her predecessors. “How are these drugs being picked for this expedited pathway? Who makes the choices?” Howard asked. “There’s a lot of secrecy going on at the regulatory body right now.”

Broadly speaking, he remarked, “the Food and Drug Administration looks to be trending towards more relaxed oversight of pharmaceuticals, aside from immunizations.”

Established History on Vaccines

Concerning vaccines, Dr. Høeg has a more documented, if problematic, track record, Howard said. She published a analysis using unverified crowd-sourced reports to determine the frequency of heart inflammation after COVID-19 immunization. She counseled the Florida surgeon general Joseph Ladapo, who allegedly have altered data to indicate COVID-19 vaccinations are pose a greater threat than they are.

Part of her “wish list” for the incoming administration featured revising guidelines for new vaccines and discontinuing “unnecessary” immunizations, she stated after the election on a online show. At the FDA, Dr. Høeg has according to sources floated the idea of barring young men from obtaining COVID-19 vaccinations.

“She is an thorough ideologue who begins with her conclusions and works backwards to accommodate the evidence in a highly deceptive, fraudulent manner,” Dr. Howard said.

Gaining Influence and a “Campaign of Retribution”

Høeg aligned with fellow dissenters, {like|